REFERENCES

1. Parkes M. Personalised medicine and genetic prediction--are we there yet? Clin Med (Lond) 2013;13:s62-4.

2. Singh S. Stratified medicine: maximizing clinical benefit by biomarker-driven health care. Nestle Nutr Inst Workshop 2016;84:91-102.

3. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-7.

4. Hamann U. Hereditary breast cancer: high-risk genes, genetic testing and clinical implications. Clin Lab 2000;46:447-61.

5. Bell J. Life sciences industrial strategy. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/650447/LifeSciencesIndustrialStrategy_acc2.pdf. [Last accessed on 1 Nov 2018].

6. Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med (Lond) 2017;17:545-51.

7. Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL. Value of supportive care pharmacogenomics in oncology practice. Oncologist 2018;23:956-64.

8. FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. [Last accessed on 1 Nov 2018].

9. Zhao X, Modur V, Carayannopoulos LN, Laterza OF. Biomarkers in pharmaceutical research. Clin Chem 2015;61:1343-53.

10. Genomics England. 100,000 genome project. Available from: https://www.genomicsengland.co.uk. [Last accessed on 1 Nov 2018].

11. UK Pharmacogenetics and Stratified Medicine Network. NHS England’s policy and infrastructure plans - Ellen Graham. Available from: http://www.uk-pgx-stratmed.co.uk/index.php/nhs-england-s-policy-and-infrastructure-plans-ellen-graham.html. [Last accessed on 1 Nov 2018].

12. U-PGx. U-PGx PREPARE study. Available from: http://upgx.eu/study. [Last accessed on 1 Nov 2018].

13. Personalized Medicine Coalition. Personalized medicine at FDA: 2017 progress report. Available from: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_2017_Progress_Report.pdf. [Last accessed on 1 Nov 2018].

14. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-4.

15. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011;71:659-71.

16. UK Pharmacogenetics and Stratified Medicine Network. Pharmacogenomics of serious adverse drug reactions - Munir Pirmohamed. Available from: http://www.uk-pgx-stratmed.co.uk/index.php/pharmacogenomics-of-serious-adverse-drug-reactions-munir-pirmohamed.html. [Last accessed on 1 Nov 2018].

17. Osanlou O, Pirmohamed M, Daly AK. Pharmacogenetics of adverse drug reactions. Adv Pharmacol 2018;83:155-90.

18. Doostparast Torshizi A, Wang K. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discov Today 2018;23:1776-83.

19. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203-14.

20. Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017;102:934-41.

21. Roberts J, Middleton A. Genetics in the 21st Century: implications for patients, consumers and citizens. Version 2. F1000Res 2017;6:2020.

22. UK Pharmacogenetics and Stratified Medicine Network. Available from: http://www.uk-pgx-stratmed.co.uk. [Last accessed on 1 Nov 2018].